January 9, 2017 09:25 AM EST
Pharma

Al­ler­gan bags two new deals, takes op­tion to buy Lyso­so­mal Ther­a­peu­tics and pays $50M for mi­cro­bio­me pact

John Carroll

Editor & Founder

Al­ler­gan swooped in­to JP Mor­gan bear­ing news of a pair of deals, ink­ing an ex­clu­sive op­tion to buy out Lyso­so­mal Ther­a­peu­tics for its neu­rode­gen­er­a­tion …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Post-Hoc: RFK vs. Vivek, and the fu­ture of US drug pol­i­cy

Trump picks vac­cine skep­tic Kennedy to lead HHS, in what would be an up­heaval of US health pol­i­cy

Ei­sai ter­mi­nates Phase 3 tri­al of Dravet drug, cit­ing re­cruit­ment chal­lenges

Boston Phar­ma­ceu­ti­cals hits Phase 2 goals as it tries to keep up with MASH com­peti­tors

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times